Citations

Clear

9 citation(s) found for "Klein, Monica".

How do I create a cost structure for cellular therapy laboratory services supporting clinical trials?
Klein, Monica S , Radel, Darcie J., Kidd, Becky D , Winters, Jeffrey L

Mayo Clinic

Transfusion | October 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/trf.70420 | PMID 42860852 Get It

Abstract Background The rapid growth of FDA‐licensed and clinical trial cell and gene therapy products is causing significant growing pains for laboratories onboarding and processing these products for clinical use. While clinical programs have traditional and supplemental reimbursement models, many services provided by the laboratories are not directly reimbursed. Compounding this issue is the increasing diversity and complexity of products with unique processing requirements leading to resource‐intensive workflows. Study Design and Methods Our institution developed a three‐tiered cost structure for services provided by the cellular therapy laboratory billed to industry‐sponsored, externally manufactured clinical trials based on the level of start‐up and per product handling complexity. A list of tasks and time required to complete the tasks was recorded to account for the complexity of the specific trial. This data was used to determine the total cost billed to onboard and carry out cell processing and handling tasks by the cellular therapy laboratory to the principal investigator of the clinical trial. Results Our tiered fee structure enabled a more accurate accounting of laboratory personnel time based on the complexity of the clinical trial products, enabling our laboratory to recoup necessary costs. Conclusion A tiered fee structure corresponding to higher levels of onboarding and administrative complexities can more accurately estimate costs to enable cell processing laboratories to remain financially sustainable and continue to deliver cell and gene therapy products to patients.
Urgent need for physician education in cell and gene therapy
Strader, Shannon , Klein, Monica S., Wiltshire, Timothy D. , Jacob, Eapen K., Levine, Bruce L., DiGuardo, Margaret , Strader, Shannon R , Smither, Fantley Clay, Smither, F. Clay , Jacob, Eapen K., Levine, Bruce L.

Mayo Clinic

Transfusion | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/trf.70333 | PMID 42473196 Get It

Leading the Way
Strader, Shannon , Smither, F Clay, Klein, Monica, Wiltshire, Timothy , Jacob, Eapen K., Ambrosio, Fabrisia , Terzic, Carmen, Strader, Shannon R , Smither, F. Clay , Klein, Monica, McDonald, Craig M , Terzic, Carmen M.

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/phm.0000000000003049 | PMID 42159177 Get It

Regenerative rehabilitation combines rehabilitation science with regenerative medicine approaches to achieve synergistic and more effective outcomes. Within the field of regenerative medicine, there has been a growing number of cell and gene therapies (CGTs) that are either approved for clinical use or actively undergoing clinical trials. Many of these therapies—especially those targeting neurological and musculoskeletal disorders—use functional outcomes as primary or secondary endpoints, prompting discussion about how physical medicine and rehabilitation (PM&R) physicians can support the integration of CGTs into clinical care. In this perspective article, we explain why physicians specializing in PM&R could take a leading role in advancing the clinical translation of CGTs. Currently, CGTs are not confined to a single medical specialty, presenting a timely opportunity for PM&R—working collaboratively with neurology, hematology, and other disciplines—to assume greater leadership and influence the development and implementation of these transformative treatments. To our knowledge, this is the first publication within PM&R literature to emphasize the importance of our specialty serving as a leader and driving force in the adoption of these therapies.
Introduction to Translating Orthobiologics and Cellular Therapies for the Musculoskeletal Provider
Strader, Shannon , Medlyn, Michael, Klein, Monica, DiGuardo, Margaret, Arthurs, Jennifer R. , Arthurs, Jennifer, Strader, Shannon R , Klein, Monica, DiGuardo, Margaret , Shapiro, Shane A.

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | March 30, 2026 | Volume: 105 | Issue: 4 | Pages: 363-369

10.1097/phm.0000000000002928 | PMID 41906240 Get It

Abstract Within the field of regenerative medicine for musculoskeletal regenerative medicine, orthobiologics and cellular therapies are evolving at a rapid pace. Exuberant ideas for new treatments often outpace their scientific evidence, which may create confusion for both patients and providers on what treatments are evidence based. Orthobiologics and cellular therapies are a subset of regenerative therapies focused on treatment of musculoskeletal disease. For the field of orthobiologics to progress, it is essential that musculoskeletal providers understand the necessary components for translating novel therapies from discovery into practice. In this article, we provide an overview of both the lexicon and regulatory processes related to translation of orthobiologics and cellular therapies along with a comparison of how to translate orthobiologics and related novel cellular therapies in hopes to dispel misinformation while promoting responsible advancements and ethical practices in medicine.
Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee ( CTSCC ) of Association for Advancement of Blood and Biotherapies (
Guleria, Indira , Connelly‐Smith, Laura , Bapat, Asawari , Klein, Monica, Jacob, Eapen K., Mahanta, Simran, Cui, Wanxing, Reich‐Slotky, Ronit , Spitzer, Thomas R. , Connelly-Smith, Laura , Bapat, Asawari, Alkhateeb, Hassan B. , Anandappa, Annabelle J. , Cui, Wanxing , Celluzzi, Christina M.

Mayo Clinic

Transfusion | January 28, 2026 | Volume: 66 | Issue: 8 | Pages: 1624-1644

10.1111/trf.70095 | PMID 41603138 Get It

A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Jacobs, Jeremy W. , Adkins, Brian D. , Stanek, C , Stephens, Laura D. , Daou, Laetitia , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Aljuboori, Omar , Harrington, Thomas J., Byrnes, Diana M. , Eichbaum, Quentin , Klapper, Ellen, Klein, Monica S., Alkhateb, Rahaf, Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bloch, Evan M. , Adkins, Brian D. , Booth, Garrett , Stanek, Caroline G , Grossman, Brenda J , Stephens, Laura , Crowe, Elizabeth P , Marques, Marisa B , Yamada, Chisa , Juskewitch, Justin E , Perez-Alvarez, Ingrid , Parsons, Meredith G , Schlueter, Annette J , Tormey, Christopher A , Yates, Sean G , Bloch, Evan M , Raval, Jay S , Jacobs, Jeremy W , Adkins, Brian David , Adkins, Brian D. , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Marques, Marisa B. , Yamada, Chisa , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Aldarweesh, Fatima , Parsons, Meredith G , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Raval, Jay S.

Mayo Clinic

Journal of Clinical Apheresis | March 30, 2025 | Volume: 40 | Issue: 2 | Pages: No page available

10.1002/jca.70017 | PMID 40145682 Get It

ABSTRACTImmune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time‐period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty‐day mortality was 3.7% (14/374), and 6‐month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs, Jeremy W. , Stanek, C , Symeonidis, Argiris , Shih, Andrew W. , Gavriilaki, Eleni , Pavenski, Katerina , Moorehead, Amy , Mingot‐Castellano, María Eva , Daou, Laetitia , Arnold, Donald M. , Henrie, Ryan , Smith, Tyler , Sreenivasan, Gayatri , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Harrington, Thomas J., Byrnes, Diana M. , Bitsani, Aikaterini , Davis, Amanda K. , Robinson, Danielle H., Eichbaum, Quentin , Kaiafa, Georgia , Klapper, Ellen, Klein, Monica S., Kotsiou, Nikolaos , Lalayanni, Chrysavgi , Mandala, Evdokia , Alkhateb, Rahaf, Fortuny, Lisandro, Mellios, Zois, Papalexandri, Apostolia, Parsons, Meredith G , Wellard, Cameron , Jia, Shiyang , Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bouzid, Raïda , Coppo, Paul, Bloch, Evan M. , Adkins, Brian D. , Stanek, Caroline G , Booth, Garrett , Symeonidis, Argiris , Shih, Andrew W , Gavriilaki, Eleni , Moorehead, Amy , Peyvandi, Flora , Mancini, Ilaria , Raval, Jay S , Mingot-Castellano, Maria Eva , Crowe, Elizabeth P , Arnold, Donald M , Yamada, Chisa , Kotsiou, Nikolaos , Aldarweesh, Fatima , Schlueter, Annette J , Tormey, Christopher A , Wood, Erica M , Wheeler, Allison P , Yates, Sean G , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Parsons, Meredith G , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Pavenski, Katerina , Peyvandi, Flora , Agosti, Pasquale , Stephens, Laura D. , Raval, Jay S. , Pai, Menaka , Marques, Marisa B. , Yamada, Chisa , Robinson, Danielle H. , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Kapsali, Eleni , Perez-Alvarez, Ingrid , Aldarweesh, Fatima , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Coppo, Paul

Mayo Clinic

American Journal of Hematology | August 13, 2024 | Volume: 99 | Issue: 11 | Pages: 2063-2074

10.1002/ajh.27458 | PMID 39136282 Get It

AbstractPrior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5‐year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere—winter (December–February); spring (March–May); summer (June–August); autumn (September–November) and Southern Hemisphere—winter (June–August); spring (September–November); summer (December–February); autumn (March–May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%–31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
Updates in the care of the alloimmunized pregnant patient: A transfusion medicine and clinical laboratory perspective
Abels, Elizabeth , Adkins, Brian D. , Booth, Garrett S. , DiGuardo, Margaret , Ding, Jia Jennifer, Guarente, Juliana , Klein, Monica, Woo, Jennifer S. , Jacobs, Jeremy W. , DiGuardo, Margaret A , Woo, Jennifer S , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Allen, Elizabeth S. , Stephens, Laura D. , Tormey, Christopher A.

Mayo Clinic

American Journal of Clinical Pathology | July 20, 2023 | Volume: 160 | Issue: 5 | Pages: 441-443

10.1093/ajcp/aqad083 | PMID 37471256 Get It